Syndicated from PubMed RSS Feeds
Targeted Massively Parallel Sequencing Provides Comprehensive Genetic Diagnosis for Patients with Disorders of Sex Development.
Clin Genet. 2012 Mar 21;
Authors: Arboleda VA, Lee H, Sanchez F, Délot E, Sandberg DE, Grody W, Nelson SF, Vilain E
Abstract
Disorders of Sex Development (DSD) are rare disorders in which there is discordance between chromosomal, gonadal, and phenotypic sex. Only a minority of patients clinically diagnosed with DSD obtains a molecular diagnosis, leaving a large gap in our understanding of the prevalence, management, and outcomes in affected patients. We created a novel DSD-genetic diagnostic tool, in which sex development genes are captured using RNA probes and undergomassively parallel sequencing. In the pilot group of 14 patients, we determined sex chromosome dosage, copy number variation, and gene mutations. In the patients with a known genetic diagnosis (obtained either on a clinical or research basis), this test identified the molecular cause in 100% (7/7) of patients. In patients in whom no molecular diagnosis had been made, this tool identified a genetic diagnosis in 2 of 7 patients. Targeted sequencing of genes representing a specific spectrum of disorders can result in a higher rate of genetic diagnoses than current diagnostic approaches. Our DSD diagnostic tool provides for first time, in a single blood test, a comprehensive genetic diagnosis in patients presenting with a wide range of urogenital anomalies.
PMID: 22435390 [PubMed - as supplied by publisher]
More...
Targeted Massively Parallel Sequencing Provides Comprehensive Genetic Diagnosis for Patients with Disorders of Sex Development.
Clin Genet. 2012 Mar 21;
Authors: Arboleda VA, Lee H, Sanchez F, Délot E, Sandberg DE, Grody W, Nelson SF, Vilain E
Abstract
Disorders of Sex Development (DSD) are rare disorders in which there is discordance between chromosomal, gonadal, and phenotypic sex. Only a minority of patients clinically diagnosed with DSD obtains a molecular diagnosis, leaving a large gap in our understanding of the prevalence, management, and outcomes in affected patients. We created a novel DSD-genetic diagnostic tool, in which sex development genes are captured using RNA probes and undergomassively parallel sequencing. In the pilot group of 14 patients, we determined sex chromosome dosage, copy number variation, and gene mutations. In the patients with a known genetic diagnosis (obtained either on a clinical or research basis), this test identified the molecular cause in 100% (7/7) of patients. In patients in whom no molecular diagnosis had been made, this tool identified a genetic diagnosis in 2 of 7 patients. Targeted sequencing of genes representing a specific spectrum of disorders can result in a higher rate of genetic diagnoses than current diagnostic approaches. Our DSD diagnostic tool provides for first time, in a single blood test, a comprehensive genetic diagnosis in patients presenting with a wide range of urogenital anomalies.
PMID: 22435390 [PubMed - as supplied by publisher]
More...